Unknown

Dataset Information

0

Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.


ABSTRACT: BACKGROUND:The China Continuation study was a separate regional expansion of the global, double-blind, placebo-controlled, randomized phase III TOURMALINE-MM1 study of ixazomib plus lenalidomide-dexamethasone (Rd) in patients with relapsed/refractory multiple myeloma (RRMM) following one to three prior therapies. METHODS:Patients were randomized (1:1) to receive ixazomib 4.0 mg or placebo on days 1, 8, and 15, plus lenalidomide 25 mg on days 1-21 and dexamethasone 40 mg on days 1, 8, 15, and 22, in 28-day cycles. Randomization was stratified according to number of prior therapies, disease stage, and prior proteasome inhibitor exposure. The primary endpoint was progression-free survival (PFS). In total, 115 Chinese patients were randomized (57 ixazomib-Rd, 58 placebo-Rd). RESULTS:At the preplanned final analysis for PFS, after median PFS follow-up of 7.4 and 6.9 months, respectively, PFS was improved with ixazomib-Rd versus placebo-Rd (median 6.7 vs 4.0 months; HR 0.598; p?=?0.035). At the preplanned final analysis of overall survival (OS), after median follow-up of 20.2 and 19.1 months, respectively, OS was improved with ixazomib-Rd versus placebo-Rd (median 25.8 vs 15.8 months; HR 0.419; p?=?0.001). On the ixazomib-Rd and placebo-Rd arms, respectively, 38 (67%) and 43 (74%) patients reported grade ?3 adverse events (AEs), 19 (33%) and 18 (31%) reported serious AEs, and 4 (7%) and 5 (9%) died on-study. The most frequent grade 3/4 AEs were thrombocytopenia (18%/7% vs 14%/5%), neutropenia (19%/5% vs 19%/2%), and anemia (12%/0 vs 26%/2%). CONCLUSIONS:This study demonstrated that PFS and OS were significantly improved with ixazomib-Rd versus placebo-Rd, with limited additional toxicity, in patients with RRMM. TRIAL REGISTRATION:ClinicalTrials.gov, NCT01564537.

SUBMITTER: Hou J 

PROVIDER: S-EPMC5500972 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.

Hou Jian J   Jin Jie J   Xu Yan Y   Wu Depei D   Ke Xiaoyan X   Zhou Daobin D   Lu Jin J   Du Xin X   Chen Xiequn X   Li Junmin J   Liu Jing J   Gupta Neeraj N   Hanley Michael J MJ   Li Hongmei H   Hua Zhaowei Z   Wang Bingxia B   Zhang Xiaoquan X   Wang Hui H   van de Velde Helgi H   Richardson Paul G PG   Moreau Philippe P  

Journal of hematology & oncology 20170706 1


<h4>Background</h4>The China Continuation study was a separate regional expansion of the global, double-blind, placebo-controlled, randomized phase III TOURMALINE-MM1 study of ixazomib plus lenalidomide-dexamethasone (Rd) in patients with relapsed/refractory multiple myeloma (RRMM) following one to three prior therapies.<h4>Methods</h4>Patients were randomized (1:1) to receive ixazomib 4.0 mg or placebo on days 1, 8, and 15, plus lenalidomide 25 mg on days 1-21 and dexamethasone 40 mg on days 1,  ...[more]

Similar Datasets

| S-EPMC5574012 | biostudies-literature
| S-EPMC4559079 | biostudies-literature
| S-EPMC5622861 | biostudies-other
| S-EPMC5482100 | biostudies-literature
| S-EPMC8732884 | biostudies-literature
| S-EPMC7027539 | biostudies-literature
| S-EPMC7810195 | biostudies-literature
| S-EPMC6269302 | biostudies-literature
| S-EPMC5980148 | biostudies-literature
| S-EPMC7873303 | biostudies-literature